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The position of the catheters relative to the tumour bed was 
measured in CT. 
Results: With sole US guidance, seven out of 10 catheters passed 
through the tumour bed. The catheter spacing was inconsistent 
and the desired goal of two rows of five equally-spaced catheters 
was not precisely achieved, with a mean spacing of 1.0 cm with 
0.7 - 1.9 cm range. Under combined EMT-US guidance, nine out 
of 10 catheters passed through the tumour bed, yielding two 
rows of five catheters with more consistent spacing, with a mean 
spacing of 1.0 cm with 0.8-1.2 cm range. 
Conclusions: This phantom experiment suggests that combined 
EMT-US guidance can help achieve consistent catheter spacing 
over the tumour bed. These results are preliminary, and a trial 
of the method is now being conducted to validate our results. 
Additional research is being conducted to translate the proposed 
navigation technique to patient trials. 
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Purpose: Endobronchial metastasis originating from primary 
cancers outside the lung are rare in comparison with 
parenchymal metastasis. External beam radiotherapy (EBRT) is 
often attempted for control of cough, hemoptysis, chest pain and 
dyspnea with variable effectiveness and potential toxicities. 
There are also limitations to re-treatment with EBRT if symptoms 
recur. Documented experience in the use of brachytherapy for 
these patients is very limited in the literature. We report a 
cohort of patients with endobronchial metastasis treated with 
high-dose rate (HDR) brachytherapy at our center. 
Methods and Materials: A prospective database was created 
from 2006-2015 including demographic, treatment and outcome 
data. Patients with endobronchial metastasis from any primary 
site outside the lung who received one or more high-dose rate 
brachytherapy treatments with iridium-192 were included. 
Cough, dyspnea, chest pain and hemoptysis were assessed and 
graded by the primary medical team as absent (0), mild (1), 
moderate (2), significant (3), and severe (4) at the time of initial 
consult and in follow up. The duration of symptom improvement 
and re-expansion of the lung documented on imaging were 
analyzed using Kaplan-Meier curves.  
Results: Thirty-five patients with endobronchial metastasis were 
identified (14 GIT, five breast, three each of 
sarcoma, lymphoma, melanoma, renal cell, two head and 
neck, one cervix and one testicle). The majority of patients 
received three fractions of 700 cGy, and 15 patients had 
received EBRT to the lung beforehand and four afterwards. 
Median symptom-free survival was 67 days and overall 
survival was 117 days. Of patients reporting the presence 
of symptoms at baseline, improvement in cough was 
documented in 75.0 % (21/28), hemoptysis in 76.4% (13/18), 
pain in 64.3% (9/14) and dyspnea in 60.0% (18/30) for a median 
of three, three, three and six months respectively. Absent to 
mild cough (n = 8), hemoptysis (n = 17), pain (n = 21), and 
dyspnea (n = 6) scores were maintained for median periods of 
two, three and four months respectively. Of the 22 patients 
who had subsequent chest imaging, re-expansion was 
documented in 32%. There were no significant toxicities 
reported. 
Conclusions: Brachytherapy appears effective in achieving 
durable symptom control of cough hemoptysis and dyspnea in 
patients with metastatic disease located in the bronchus. It can 
be used in combination with or as an alternative to external 
beam radiotherapy, and should be considered routinely where 
available in this patient population. Further studies are required 
to better characterize expected symptom improvement and lung 
re-expansion rates. 
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Purpose: Endobronchial complications of primary and metastatic 
lung malignancy contribute to considerable patient morbidity 
and adversely affect quality-of-life with symptoms of dyspnea 
and hemoptysis. Endobronchial High-Dose Rate (HDR) 
Brachytherapy is an efficacious treatment strategy indicated for 
large obstructing endobronchial lesions not amenable for surgical 
resection, combination treatment with external beam 
radiotherapy for potentially improved local control and for the 
palliation of symptoms in the re-treatment setting. The purpose 
of this study was to explore the clinical features and outcomes 
in a consecutive series of patients treated for malignant 
endobronchial obstruction at a single institution. 
Methods and Materials: A retrospective analysis was performed 
on all consecutive patients treated at the Cancer Centre of 
Southeastern Ontario with endobronchial HDR Brachytherapy 
between November 2012 and March 2015. The demographic and 
clinical characteristics were collected and overall survival and 
symptomatic progression-free survival are reported. 
Results: Twenty-eight consecutively treated patients (17 male 
and 11 female) were identified for review. The average age at 
the time of treatment was 69.12 years. The majority of patients 
had a histopathological diagnosis of lung cancer (n = 21 non-small 
cell lung cancer, n = 1 small cell lung cancer) while the 
remainder (n = 6) had metastatic disease from other primaries. 
Fifteen patients had metastatic disease at presentation and nine 
were treated with systemic therapy prior to brachytherapy. The 
major indication for treatment included dyspnea (n = 18) and 
hemoptysis (n = 10) with 12 patients identified to have complete 
bronchial occlusion by bronchoscopy. Two patients were treated 
in a critical care setting and discharged home with stabilization 
of symptoms. The median overall survival for the group was 17.58 
weeks while the median symptomatic progression-free survival 
was 9.82 weeks. 
Conclusions: Endobronchial HDR brachytherapy remains an 
efficacious treatment strategy for patients presenting with 
malignant bronchial occlusion causing dyspnea and/or 
hemoptysis. Our experience demonstrates that carefully-
selected patients can experience effective palliation of 
symptoms despite an overall poor prognosis for the group. While 
limited, our experience also demonstrates that some patients 
with massive-hemoptysis or respiratory failure may benefit from 
treatment in the hands of a skilled brachytherapy team. 
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Purpose: The dosimetry of trans-perineal interstitial 
brachytherapy (ISBT) treatment of gynecological malignancies 
can be significantly affected by the presence of rectal gas. This 
study evaluates the impact of using a rectal tube on dosimetric 
factors. 
Methods and Materials: Twenty-nine patients treated between 
August and December 2015 at our institution were included in a 
prospective registry trial. Data on the use of a rectal tube and 
dosimetric parameters were collected. Rectal volume, maximum 
dose to 2 cc of the rectum contour (D2cc) and the minimum dose 
to 90% of the high-risk clinical target volume (HR-CTV D90) was 
compared using a t-test for the rectal tube and no rectal tube 
cohorts. The rectal volume was measured from 1cm above and 
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below the superior and inferior extents of the target volume. For 
patients that received planning CT scans both immediately 
before and after rectal tube insertion, treatment plans were 
generated retrospectively with matched rectal D2cc. The 
resulting plans were compared visually, and the dose received by 
the HR-CTV D90 was compared. 
Results: All patients were treated with a combination of external 
beam radiotherapy to the pelvis and 3-5 fractions of high-dose 
rate interstitial brachytherapy in twice daily fractions. Ten and 
19 patients were treated without and with a rectal tube 
respectively. Rectal volume between the first and third fractions 
was significantly more reproducible in the rectal tube group (p = 
0.038). There was a significant increase in the HRCTV D90 with 
the use of a rectal tube (mean HRCTV D90 99.5% in the non-rectal 
tube group and 106% in the rectal tube group, p = 0.002). There 
was no significant difference in the D2cc rectum between the 
two groups (p = 0.77). Seven patients received a planning CT 
immediately prior to and immediately after rectal tube 
insertion, and plans with matched rectal doses were generated 
(11 pairs of plans). For these patients there was no significant 
difference in the HRCTV D90 between the rectal tube and no 
rectal tube plans (p = 0.187). There were seven plans in which 
the use of a rectal tube increased the HRCTV D90, and four plans 
in which it lowered the HRCTV D90. On visual inspection of these 
plans the rectal tube appeared to push the rectal wall anteriorly. 
Conclusions: For the patients included in this study, the use of 
a rectal tube in ISBT significantly reduced variability in rectal 
volume between the first and third treatment fractions. Overall 
the use of a rectal tube was associated with a significantly 
increased dose to the HRCTV D90, and no significant change in 
the D2cc to the rectum. However, for some patients the use of a 
rectal tube may worsen dosimetric parameters if the rectum is 
pushed anteriorly towards the target volume by the relatively 
stiff rectal tube. Further work is required in identifying patients 
who may not benefit from use of a rectal tube. 
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Purpose: Brachytherapy (BT) techniques for cervical cancer (CC) 
in Canada have changed over the last decade, with evolution to 
HDR and image-guided BT. However, there are currently no 
national data on the use of interstitial BT (IBT) in the 
management of patients with CC. The purpose of this study was 
to document IBT utilization in Canadian centres, as well as 
update details of CC BT practices. 
Methods and Materials: All Canadian centres with gynecologic 
BT services (n = 32) were identified, and one gynecology 
radiation oncologist per centre was sent a 33-item e-mail 
questionnaire regarding the centre’s practice for CC BT in 2015. 
Responses are reported and compared with practice patterns 
identified in a 2012 Canadian survey.  
Results: The response rate was 81% (26 of 32 centres). The 
majority (92%) used high-dose rate (HDR) BT, identical to the 
2012 survey. Ninety-three percent (24 of 26) of centres had 
transitioned to 3D MRI/CT based planning by 2015, versus 80% in 
2012. Sixty-five percent of centres incorporated MRI for 
treatment planning in 2015 compared to 37% in 2012; the 
majority (13/16) using a combination of MRI and CT. Fifty 
percent (13 of 26 centres) had the capacity to perform IBT; in 
those that did not, 50% referred patients to other centres who 
performed the procedure. Of centres performing IBT, the 
majority (nine out of 13) used free-hand template-based 
techniques. For IBT, a median of five (range 2-20) 
needles/catheters was used and an average of four (range 1-5) 
fractions were delivered. Catheters were placed using a variety 
of image-guidance modalities: pre-op imaging (54%), intra-op 
MRI (8%), intra-op CT (23%), and intra-op U/S (46%). The majority 
(77%) of centres performing IBT used inverse planning 
techniques. The most common dose/fractionation schedules 
were 6 Gy x 5 fractions (40%), 8 Gy x 3 fractions (19%) and 7 Gy 
x 4 fractions (15%). 
Conclusions: In Canada, treatment of cervical cancer continues 
to evolve. Interstitial BT has been adopted by half of the 
responding centres. As more centres move to MRI-based image-
guided treatment planning, IBT will become an even more 
integral part of cervical cancer treatment. 
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Purpose: Risk stratification for localized prostate cancer can 
assist clinicians select the most appropriate treatment for their 
patients based on baseline clinical factors. The present study 
aimed to externally validate a recently published nomogram for 
low-dose rate (LDR) brachytherapy that was developed in 
patients treated in several Canadian centers. 
Methods and Materials: Patients receiving LDR brachytherapy at 
the Centre Hospitalier de l’Université de Montréal (CHUM) for 
localized prostate cancer between 2005 and 2015 and with a 
minimum of six months of follow up were eligible for analysis (n 
= 903). External validation was performed on the ProCaRS 
nomogram for LDR-brachytherapy to predict five-year 
biochemical failure free survival (BFFS). This was performed 
using calibration plots of nomogram predicted probability 
compared to corresponding Kaplan-Meier five-year BFFS 
estimates. 
Results: Mean age of the validation cohort was 65 years and 
median baseline PSA was 5.5 ng/mL. All patients had T1 (75%) or 
T2 (25%) disease and most had either Gleason 6 (70%) or Gleason 
7 (29%). Mean D90 was 161 Gy (standard deviation [SD] 25) and 
10% of patients received D90 < 130 Gy. Reasonable nomogram 
calibration was observed (R2 = 0.778), however this produced an 
underestimation of the true survival for all values based on the 
point estimates, particularly for nomogram predicted survival < 
90% and 92-94%. This finding may be partially attributed to the 
limited number of patients with observed BFFS < 90% and a 
shorter follow up in the CHUM compared to the original cohort 
used to develop the nomogram. A sensitivity analysis was 
performed to determine an adjustment to the nomogram 
predicted probability to improve calibration. Applying an 
adjustment of +3.24% to the nomogram predicted probability 
yielded a more favourable calibration for both nomograms 
(adjusted R2 = 0.813). 
Conclusions: We believe the LDR brachytherapy ProCaRS 
nomogram is a clinically useful tool that may help clinicians in 
treatment selection and outcome prediction for prostate cancer. 
For instance, it may be useful in counseling patients with 
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